Atezolizumab plus Tiraglolumab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Squamous Cell Carcinoma of the Anal Canal
Conditions
Squamous Cell Carcinoma of the Anal Canal
Trial Timeline
Feb 14, 2023 → Jun 1, 2028
NCT ID
NCT05661188About Atezolizumab plus Tiraglolumab
Atezolizumab plus Tiraglolumab is a phase 2 stage product being developed by Roche for Squamous Cell Carcinoma of the Anal Canal. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05661188. Target conditions include Squamous Cell Carcinoma of the Anal Canal.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05661188 | Phase 2 | Recruiting |
Competing Products
20 competing products in Squamous Cell Carcinoma of the Anal Canal